{rfName}
No

Indexed in

License and use

Icono OpenAccess

Citations

43

Altmetrics

Analysis of institutional authors

Gamez-Chiachio MAuthorSarrió DCorresponding AuthorMoreno-Bueno GCorresponding Author

Share

October 10, 2022
Publications
>
Review
Sí

Novel Therapies and Strategies to Overcome Resistance to Anti-HER2-Targeted Drugs

Publicated to:Cancers. 14 (18): 4543- - 2022-09-01 14(18), DOI: 10.3390/cancers14184543

Authors: Gamez-Chiachio, Manuel; Sarrio, David; Moreno-Bueno, Gema

Affiliations

Centro de Investigación Biomédica en Red de Cáncer , MD Anderson Cancer Center, Madrid , Universidad Autónoma de Madrid - Author
Centro de Investigación Biomédica en Red de Cáncer , Universidad Autónoma de Madrid - Author
Ctr Invest Biomed Red Oncol CIBERONC, Madrid 28029, Spain - Author
MD Anderson Int Fdn, Madrid 28033, Spain - Author
Univ Autonoma Madrid CSIC, Med Fac, Biochem Dept, IdiPaz, Madrid 28029, Spain - Author
See more

Abstract

The prognosis and quality of life of HER2 breast cancer patients have significantly improved due to the crucial clinical benefit of various anti-HER2 targeted therapies. However, HER2 tumors can possess or develop several resistance mechanisms to these treatments, thus leaving patients with a limited set of additional therapeutic options. Fortunately, to overcome this problem, in recent years, multiple different and complementary approaches have been developed (such as antibody–drug conjugates (ADCs)) that are in clinical or preclinical stages. In this review, we focus on emerging strategies other than on ADCs that are either aimed at directly target the HER2 receptor (i.e., novel tyrosine kinase inhibitors) or subsequent intracellular signaling (e.g., PI3K/AKT/mTOR, CDK4/6 inhibitors, etc.), as well as on innovative approaches designed to attack other potential tumor weaknesses (such as immunotherapy, autophagy blockade, or targeting of other genes within the HER2 amplicon). Moreover, relevant technical advances such as anti-HER2 nanotherapies and immunotoxins are also discussed. In brief, this review summarizes the impact of novel therapeutic approaches on current and future clinical management of aggressive HER2 breast tumors.

Keywords

antiher2 therapiesher2 breast cancerAntiher2 therapiesHer2 breast cancerResistance

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Cancers due to its progression and the good impact it has achieved in recent years, according to the agency Scopus (SJR), it has become a reference in its field. In the year of publication of the work, 2022, it was in position , thus managing to position itself as a Q1 (Primer Cuartil), in the category Oncology.

From a relative perspective, and based on the normalized impact indicator calculated from World Citations provided by WoS (ESI, Clarivate), it yields a value for the citation normalization relative to the expected citation rate of: 2.7. This indicates that, compared to works in the same discipline and in the same year of publication, it ranks as a work cited above average. (source consulted: ESI Nov 14, 2024)

This information is reinforced by other indicators of the same type, which, although dynamic over time and dependent on the set of average global citations at the time of their calculation, consistently position the work at some point among the top 50% most cited in its field:

  • Weighted Average of Normalized Impact by the Scopus agency: 2.24 (source consulted: FECYT Feb 2024)
  • Field Citation Ratio (FCR) from Dimensions: 7.05 (source consulted: Dimensions Aug 2025)

Specifically, and according to different indexing agencies, this work has accumulated citations as of 2025-08-22, the following number of citations:

  • WoS: 12
  • Scopus: 13
  • Europe PMC: 10

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-08-22:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 49.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 49 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 1.
  • The number of mentions on the social network X (formerly Twitter): 1 (Altmetric).

It is essential to present evidence supporting full alignment with institutional principles and guidelines on Open Science and the Conservation and Dissemination of Intellectual Heritage. A clear example of this is:

  • The work has been submitted to a journal whose editorial policy allows open Open Access publication.

Leadership analysis of institutional authors

There is a significant leadership presence as some of the institution’s authors appear as the first or last signer, detailed as follows: First Author (GAMEZ CHIACHIO, MANUEL) and Last Author (MORENO BUENO, GEMA).

the authors responsible for correspondence tasks have been SARRIO LOPEZ, JOSE DAVID and MORENO BUENO, GEMA.